Low-Dose Methotrexate for the Prevention of Atherosclerotic Events | Zendy

Paul M. Ridker | Zendy; Brendan M. Everett | Zendy; Aruna D. Pradhan | Zendy; Jean MacFadyen | Zendy; Daniel H. Solomon | Zendy; Elaine Zaharris | Zendy; Virak Mam | Zendy; Ahmed Hasan | Zendy; Yves Rosenberg | Zendy; Erin Iturriaga | Zendy; Milan Gupta | Zendy; Michelle Tsigoulis | Zendy; Subodh Verma | Zendy; Michael Clearfield | Zendy; Peter Libby | Zendy; Samuel Z. Goldhaber | Zendy; Roger L. Seagle | Zendy; Cyril Ofori | Zendy; Mohammad G. Saklayen | Zendy; Samuel Butman | Zendy; Narendra Singh | Zendy; Michel Le May | Zendy; Olivier F. Bertrand | Zendy; James Johnston | Zendy; Nina P. Paynter | Zendy; Robert J. Glynn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

Author(s) -

Paul M. Ridker,

Brendan M. Everett,

Aruna D. Pradhan,

Jean MacFadyen,

Daniel H. Solomon,

Elaine Zaharris,

Virak Mam,

Ahmed Hasan,

Yves Rosenberg,

Erin Iturriaga,

Milan Gupta,

Michelle Tsigoulis,

Subodh Verma,

Michael Clearfield,

Peter Libby,

Samuel Z. Goldhaber,

Roger L. Seagle,

Cyril Ofori,

Mohammad G. Saklayen,

Samuel Butman,

Narendra Singh,

Michel Le May,

Olivier F. Bertrand,

James Johnston,

Nina P. Paynter,

Robert J. Glynn

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1809798

Subject(s) - methotrexate , medicine

Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether an alternative approach to inflammation inhibition with low-dose methotrexate might provide similar benefit.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research